Aktuelle Optionen zur Behandlung der Riesenzellarteriitis

Abstract

To prevent serious complications such as permanent loss of vision and structural vascular damage, treatment must be initiated quickly in patients with giant-cell arteritis (GCA). So far, usually long-term corticosteroids in cumulative high dosages have been the standard therapy option. However, steroids are often insufficient to achieve adequate disease control and are associated with serious adverse events. Therefore, steroid-sparing therapy options are the focus of interest.

Um potenziell schwere Komplikationen zu vermeiden, muss bei Patienten mit Riesenzellarteriitis (RZA) zügig eine Behandlung eingeleitet werden. Bisher waren meist langfristig verabreichte Glukokortikoide (GC) die Standardbehandlung. Damit lässt sich die Erkrankung häufig jedoch nur unzureichend kontrollieren, zudem besteht das Risiko GC-induzierter Langzeitschäden. Daher stehen steroidsparende Therapieoptionen im Mittelpunkt des Interesses.

Schlüsselwörter

Riesenzellarteriitis - Pathogenese - Therapie - Glukokortikoide - steroidsparende Therapie

Key words

giant cell arteritis - pathogenesis - therapy - corticosteroids - steroid-sparing therapy

• Literatur

• 1 Carmona FD, Vaglio A, Mackie SL. et al. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. Am J Hum Genet 2017; 100: 64-74
• 2 Rhee RL, Grayson PC, Merkel PA. et al. Infections and the risk of incident giant cell arteritis: a population-based, case-control study. Ann Rheum Dis 2017; 76: 1031-1035
• 3 Ciccia F, Rizzo A, Ferrante A. et al. New insights into the pathogenesis of giant cell arteritis. Autoimmun Rev 2017; 16: 675-683
• 4 Labarca C, Koster MJ, Crowson CS. et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 2016; 55: 347-356
• 5 Baslund B, Helleberg M, Faurschou M. et al. Mortality in patients with giant cell arteritis. Rheumatology (Oxford) 2015; 54: 139-143
• 6 Wilson JC, Sarsour K, Collinson N. et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Semin Arthritis Rheum 2017; 46: 819-827
• 7 Hellmich B. Management der Polymyalgia rheumatica und der Großgefäßvaskulitiden. Internist 2016; 57: 1069-1078
• 8 Proven A, Gabriel SE, Orces C. et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 703-708
• 9 Schmidt J, Smail A, Roche B. et al. Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis. Arthritis Rheum 2016; 68: 1477-1482
• 10 Mukhtyar C, Guillevin L, Cid MC. et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-323
• 11 Bienvenu B, Ly KH, Lambert M. et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Intern 2016; 37: 154-165
• 12 Mahr AD, Jover JA, Spiera RF. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-2797
• 13 De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136-138
• 14 Schaufelberger C, Möllby H, Uddhammar A. et al. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 2006; 35: 327-329
• 15 Loock J, Henes J, Kötter I. et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 2012; 30 (Suppl. 70) S70-S76
• 16 Seitz M, Reichenbach S, Bonel HM. et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series. Swiss Med Wkly 2011; 17: 141
• 17 Villiger PM, Adler S, Kuchen S. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1921-1927
• 18 Stone JH, Tuckwell K, Dimonaco S. et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377: 317-328
• 19 Hoffman GS, Cid MC, Rendt-Zagar KE. et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 2007; 146: 621-630
• 20 Martinez-Taboada VM, Rodríguez-Valverde V, Carreño L. et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625-630
• 21 Seror R, Baron G, Hachulla E. et al. Adalimumab for steroid sparing in patients with giant cell arteritis: results of a multicentre randomized controlled trial. Ann Rheum Dis 2014; 73: 2074-2081
• 22 Langford CA, Cuthbertson D, Ytterberg SR. et al. Vasculitis Clinical Research Consortium. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheum 2017; 69: 837-845
• 23 Conway R, O’Neill L, O’Flynn E. et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 2016; 75: 1578-1579
• 24 Martinez-Taboada VM, Lopez-Hoyos M, Narvaez J. et al. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev 2014; 13: 788-794
• 25 Mollan SP, Sharrack N, Burdon MA. et al. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev 2014; 8: CD010453